Just as chemotherapy often requires several drugs to combat resistance in cancerous cells, successful antimicrobial
therapy against some pathogens requires a combination of drugs.
Not exact matches
Made into a permanent programme in 2009, it set out to sequence the genomes of potential bioterror agents, explore new drug technologies and develop «broad - spectrum»
therapies that would work
against multiple bacterial and viral
pathogens — especially haemorrhagic fever viruses such as Ebola and Marburg.
NIAID's biodefense research is integrated into its larger emerging and re ‐ emerging infectious diseases portfolio that uses sophisticated genomic and proteomic platforms focused on developing broad ‐ spectrum
therapies effective
against entire classes of
pathogens.